Nevertheless, approval of siRNA drugs such as patisiran (OnpattroR) composed as a nanocapsule decorated with the protein ApoE that mediates uptake into the liver, where transported siRNA can knockdown transthyretin to treat patients with hereditary transthyretin-mediated amyloidosis [54, 55] shows the general power of RNAi. Here, TTR is linked to amyloidosis.